Marimed (MRMD) Income from Non-Controlling Interests (2016 - 2026)
Marimed's (MRMD) quarterly Income from Non-Controlling Interests came in at $18000.0 in Q1 2026, down 43.75% year-on-year from $32000.0 in Q1 2025, and up 280.0% on a QoQ basis from -$10000.0 in Q4 2025.
Marimed (MRMD) Income from Non-Controlling Interests (2016 - 2026) Analysis & Trends
Marimed (MRMD) has 11 years of Income from Non-Controlling Interests data on file, last reported at $18000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 43.75% year-over-year to $18000.0 in Q1 2026; TTM through Mar 2026 was $14000.0, a 77.78% decrease from a year earlier, with the FY2025 full-year figure at $28000.0, down 24.32% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $18000.0, up from -$10000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for MRMD reached as high as $73000.0 in Q2 2022 and fell as low as -$19000.0 in Q1 2023.
- Historically, Income from Non-Controlling Interests has averaged $14882.4 across 5 years, with a median of $12000.0 in 2024.
- Across the five-year window, Income from Non-Controlling Interests jumped 650.0% in 2023 and tumbled 433.33% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $4000.0 in 2022, then soared by 650.0% to $30000.0 in 2023, then sank by 90.0% to $3000.0 in 2024, then tumbled by 433.33% to -$10000.0 in 2025, then jumped by 280.0% to $18000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $18000.0 in Q1 2026, -$10000.0 in Q4 2025, and $7000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.58 Bn | 86.72 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.33 Bn | 30.39 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.93 Bn | 16.62 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | - |
| 10 | Marimed | 23.85 Mn | 14.02 Mn | 15.28 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | -10,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Sep 30, 2023 | -10,000.00 |
| Jun 30, 2023 | 23,000.00 |
| Mar 31, 2023 | -19,000.00 |
| Dec 31, 2022 | 4,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | 53,000.00 |
| Dec 31, 2021 | 110,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Jun 30, 2021 | 96,000.00 |